ACH 2024 Sci Rep Impact of KDM6B Mosaic Brain Knockout On Synaptic
ACH 2024 Sci Rep Impact of KDM6B Mosaic Brain Knockout On Synaptic
ACH 2024 Sci Rep Impact of KDM6B Mosaic Brain Knockout On Synaptic
com/scientificreports
Autism spectrum disorders (ASD) and neurodevelopmental disorders are a group of clinically heterogeneous
conditions that are characterized by changes in social skills, attention deficits, hyperactivity and cognition. These
disorders can cause difficulties with social communication and interaction, as well as restricted, repetitive, and
stereotyped patterns of b ehavior1. People with ASD often have co-occurring conditions including epilepsy,
depression, anxiety, and h yperactivity2, having significant impact on the individual’s everyday life. The com-
plexity and heterogeneity of ASD pathogenesis is mainly due to the large number of ASD-related genetic varia-
tions including copy number variants, single nucleotide polymorphism, deletions and duplications according to
SFARI gene d atabase3. Moreover, the target gene function is quite diverse leading to abnormalities in neuronal
communication, cytoskeleton formation and dynamics, chromatin regulation, and gene e xpression4–8. Over the
last decade, special emphasis has been given to mutations in chromatin regulating genes where new gene vari-
ants have been described that could explain the genetic complexity of A SD9. However, the precise mechanisms
through which these mutations contribute to ASD phenotypes remain largely elusive.
Several studies have focused on unraveling the role that mutations or knockout (KO) of chromatin associated
genes have on the appearance of ASD phenotypes, including Chromodomain helicase DNA binding protein 8
(CHD8), Lysine demethylase 6A (KDM6A), and Lysine methyltransferase 2C (KMT2C)10–12. Recently, one of
the largest whole exome sequencing studies, showed that one of the highest risk genes for ASD is lysine dem-
ethylase 6b (KDM6B), also known as JMJD3 (Jumonji domain-containing protein-3)9. KDM6B functions as a
histone tail demethylase specifically targeting histone H3 lysine 27 trimethylation (H3K27me3)13. In its role as
a demethylase of H3K27, it counteracts the repressive function of the Polycomb repressive complex 2 (PRC2)14,
1
Constantine‑Paton Research Laboratory, Instituto de Ciencias Biomédicas, Facultad de Medicina y Facultad de
Ciencias de la Vida, Universidad Andres Bello, Santiago, Chile. 2Programa de Doctorado en Ciencias, Mención
Neurociencia, Universidad de Valparaíso, Valparaíso, Chile. 3Instituto de Neurociencias, Centro Interdisciplinario
de Neurociencia de Valparaíso (CINV), Facultad de Ciencias, Universidad de Valparaíso, 2340000 Valparaiso,
Chile. 4School of Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile. 5Molecular Biology
and Bioinformatics Lab, Program in Molecular Biology and Bioinformatics, Center for Biomedical Research
and Innovation (CIIB), Universidad de Los Andes, Santiago, Chile. 6Millennium Nucleus of Neuroepigenetics
and Plasticity (EpiNeuro), Santiago, Chile. 7These authors contributed equally: Bastian Brauer and Carlos
Ancatén-González. *email: [email protected]; [email protected]
Vol.:(0123456789)
www.nature.com/scientificreports/
thereby facilitating the induction of gene e xpression15. KDM6B has been widely studied for its role associated with
cancer aggressiveness and progression, as well as its involvement in brain neurogenesis, neuron differentiation,
maturation, survival, and in neurological disorders16–19. Full KDM6B KO animals die at birth due to respiratory
deficits20, thus most studies have used conditional or heterozygous animals. Heterozygous KDM6B KO mice
reportedly display hyperactivity, social and cognitive deficits21. However, the synaptic mechanisms underlying
these observed behaviors were not i nvestigated21. Using conditional KO in cerebellar granule neurons, it has been
shown that the correct control and dynamics of H3K27me3 deposition is needed for neuronal m aturation22. In
addition, conditional knockout of KDM6B in excitatory neurons causes loss of synaptic activity, spine density,
and synaptic vesicle number likely by dysregulation of VGLUT1/2 gene e xpression21,21.
Given its critical role in regulating chromatin structure and gene transcription, dysregulation of KDM6B
has been implicated in various neurodevelopmental disorders, including ASD 21,24,25. Human genetic studies
have identified over 130 likely pathogenic rare variants in the KDM6B gene, highlighting its significance in neu-
rodevelopment, however only 3 confirmed variants with ASD phenotype have been validated3. Notably, studies
of more than 85 variants across the KDM6B gene in humans have shown a myriad of phenotypes. However, a
common denominator in all of them is the presence of cognitive d eficits26. This underscores the importance
of gaining insight into the mechanisms and behavioral outcomes of KDM6B mutations and how they relate to
autistic-like behaviors and brain function.
Here we utilized the CRISPR/Cas9 system delivered via AAV to create a whole-brain mosaic knockout (mKO)
of Kdm6b at postnatal day 1, with the aim of investigating its role in controlling behavior and the functional
consequence on synaptic mechanisms associated with these behaviors. As anticipated, KDM6B mKO animals
exhibited reduced KDM6B expression, consequently leading to an increase in H3K27me3. Additionally, we
observed hyperactivity, repetitive behaviors, social impairment, and cognitive deficits. Notably, these findings cor-
relate with a significant impairment of synaptic plasticity in the hippocampus, and more specifically a significant
disruption in NMDA receptor (NMDAR)-mediated excitatory post-synaptic currents, which may underlie the
observed cognitive effects. Our results demonstrate the feasibility of modeling Kdm6b loss-of-function muta-
tions using CRISPR/Cas9, providing an additional platform to study the cellular and molecular mechanisms
underlying mutations associated with ASD.
Results
Editing of the Kdm6b gene to generate mosaic brain knockout
To elucidate the role of KDM6B in the pathogenesis of ASD, we employed the CRISPR/Cas9 system to knock out
its expression in cultured neurons and animal brain, as previously described10,27,28. We designed four sgRNAs
targeting exon 6 of Kdm6b (Fig. 1A), considering its conservation across all isoforms. These sgRNAs (KDM6B
KO1-4) were tested in cultured neurons from Cas9KI animals transducing with AAVs coding for CRISPR/
Cas9 at 3 days in vitro (DIV). At 10 DIV, RT-qPCR from these neurons was conducted to assess KO efficiency
revealing that all of them downregulated Kdm6b expression (Fig. 1B). KDM6B KO4 showed the best efficiency
downregulating KDM6B expression in vitro by approximately 70%. Subsequently, we utilized this sgRNA to
conduct our in vivo experiments.
To evaluate whether CRISPR/Cas9 induced Kdm6b KO produces autistic-like behaviors and explore poten-
tial underlying mechanisms, we utilized intracerebroventricular delivery of AAV encoding KDM6B KO4 and
TdTomato as fluorescence marker to determine transduction efficiency. This methodology ensures efficient
transduction of brain cells as previously d escribed10,27,28. Cas9KI animals received injections at P1 to produce
KDM6B mKO, and behavioral testing started at eight weeks. For inclusion in the analyses, animals had to meet
three criteria: 1. Display a widespread fluorescent label throughout the entire brain, 2. Exhibit a positive T7
endonuclease I assay confirming gene editing, and 3. Demonstrate a reduction in KDM6B expression of at least
50%. Nine control and KDM6B mKO animals met the criteria and were included in the final analyses. Following
behavioral or electrophysiological analyses, animals were imaged to determine transduction efficiency, revealing
widespread transduction including CA1, CA3 and DG in the hippocampus (Fig. 1C). Using hippocampal tis-
sue from transduced animals, the T7 endonuclease I assay for gene editing showed that all nine KDM6B mKO
animals were positive for editing at the locus (Fig. 1D). Furthermore, RT-qPCR revealed that transduced animals
exhibited an approximate 70% reduction in mRNA levels (Fig. 1E), and western blot analyses of mKO animals
show a significant reduction in KDM6B protein expression (Fig. 1F). In addition, digital PCR assay shows a
significant reduction in the number of copies of KDM6B cDNA in hippocampal tissue of KDM6B mKO animals
(Fig. 1G), confirming the reduction of the expression of Kdm6b after gene editing.
KDM6B is an enzyme responsible for catalyzing histone H3 lysine 27 demethylation, leading to the activa-
tion of gene targets, counteracting the repressive role of the PRC2 complex13,15. Consequently, we hypothesized
that knocking out Kdm6b would result in an increase in total H3K27me3 in brain tissue. As anticipated, our
observations confirmed that KDM6B mKO animals exhibit a global increase in this histone tail modification
(Fig. 1H-I). These results indicate that our strategy targeting Kdm6b can efficiently reduce its expression in the
entire brain and consequently increase global H3K27me3.
Vol:.(1234567890)
www.nature.com/scientificreports/
Fig. 1. Knockout of Kdm6b by gene editing. (A) Scheme showing exon 6 of Kdm6b genomic sequence and the position where
the designed sgRNAs bind to the genomic sequence. In green is sgRNA-4 that is used for all in vivo experiments. (B) Cultured
cortical neurons were transduced with sgRNAs and Cas9 to determine sgRNA efficiency. At 10 DIV RT-qPCR was conducted
to determine expression levels of KDM6B relative to GAPDH. (C) Representative image of brain slice and high magnification
of CA1, CA3 and DG of the hippocampus after transduction by intracerebroventricular injection of CRISPR/Cas9. (D) T7
endonuclease I assay from transduced cortical tissue of injected animals. (E) RT-qPCR to determine expression levels of
KDM6B relative to GAPDH in transduced cortical tissue of injected animals. (F) Representative western blot of KDM6B and
N-Cadherin as loading control in WT and KDM6B mKO animals. (G) Digital PCR assay to determine KDM6B cDNA copies/
µl in WT and KDM6B mKO animals (WT n = 3; KDM6B mKO n = 9) (H) Representative image of western blot analysis of
total H3 histone, and H3K27me3. (I) Quantification of the relative expression of H3K27me3 from cortical tissue extracted
from 6 control or KDM6B mKO animals. Bars represents mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Students t-test was
used to determine significance compared to control condition. Scale bar = 1000μm and 100μm for high magnification images.
Vol.:(0123456789)
www.nature.com/scientificreports/
mKO animals using the accelerated rotarod apparatus. We found that KDM6B mKO animals spent more time
on the rotarod than control animals (Fig. 2A). The presence of anxiety-like behaviors is recognized as a dis-
tinctive feature in both human and animal cases of ASD1,10,27,29,30. Therefore, we investigated whether KDM6B
mKO animals exhibited this phenotype. Using the open field test, we allowed the animals to freely explore for
10 min and measured their location and movements in the arena (Fig. 2B). Like the rotarod test, KDM6B mKO
animals traveled a significantly longer distance than control animals in the arena (Fig. 2C). However, KDM6B
mKO animals spent a similar amount of time than control animals in the center of the arena (Fig. 2D) and in
the periphery (Fig. 2E), indicating that KDM6B mKO animals do not exhibit anxiety behaviors. To confirm this
finding, we conducted the light and dark, and zero maze tests. In the light–dark apparatus, animals were placed
in the dark box and allowed to explore for 10 min (Fig. 3A). The test revealed no differences in total entries
(Fig. 3B) or time spent (Fig. 3C) in the illuminated zone between KDM6B mKO and controls. However, we did
find a significant difference in the distance traveled in the illuminated zone (Fig. 3D). Moreover, in the zero
maze (Fig. 3E), KDM6B mKO and control animals spent a similar amount of time in the open zone (Fig. 3F)
but KDM6B mKO mice exhibited an increased number of entries to the open zone compared to control animals
(Fig. 3G). Such difference can be attributed to the hyperactivity displayed by the animals, leading them to cover
longer distances and enter open zones more frequently. Then, animals underwent the marble burying test to
assess repetitive behaviors and anxiety where KDM6B mKO animals buried a significantly greater number of
marbles compared to control animals (Fig. 3H). Lastly, when grooming episodes were quantified, KDM6B mKO
animals displayed a significantly higher count of grooming episodes compared to control animals (Fig. 3I). Alto-
gether these findings suggest that KDM6B mKO animals exhibit limited anxiety as shown in the marble burying
test and in addition animals show significant hyperactivity and repetitive behaviors.
Fig. 2. Hyperactivity in KDM6B mKO animals. (A) Time spent on the rotarod apparatus. (B) Representative
trace plots of open field test in Control and KDM6B mKO animals. (C–E) Quantification of the total distance
travelled (C), time spent in the center area (D), time spent in the periphery (E). Bars represents mean ± SEM.
Students t-test was used to determine significance compared to control condition. **p < 0.01, n = 9 animals for
Control and KDM6B mKO animals. ns = non-significant.
Vol:.(1234567890)
www.nature.com/scientificreports/
Fig. 3. KDM6B mKO animals display repetitive behaviors. (A) Representative trace plots of dark and light
test (top = Control; bottom = KDM6B mKO). (B–D) Quantification of the number of entries to illuminated
zone (B), the time spent in the illuminated zone (C), and the distance travelled in the illuminated zone (D). (E)
Representative trace plots of the zero-maze test (top = Control; bottom = KDM6B mKO). (F–G) Quantification
of the time spent in the open zone (F), and the total entries to the open zone (G) in the zero maze. (H)
Quantification of the number of marbles buried during the marble burying test. (I) Quantification of the self-
grooming behavior shown by Control or KDM6B mKO animals. Bars represents mean ± SEM. Students t-test
was used to determine significance compared to control condition. *p < 0.05, n = 9 animals for Control and
KDM6B mKO animals. ns = non-significant.
the social deficits observed in the 3-chamber test, we employed the direct social interaction paradigm. During
this test, KDM6B mKO and control animals were given the opportunity to interact within a clear box for 10 min,
and their interactions were recorded for evaluation. Specifically, we focused on observing sniffing and groom-
ing behaviors during this time. Our analysis revealed that social sniffing between animals showed no significant
differences in nose-nose (N–N) interactions (Fig. 4C) or nose–head (N–H) interactions (Fig. 4D). However,
upon evaluating nose–anogenital (N–A), a significant decrease in KDM6B mKO animals was observed (Fig. 4E),
demonstrating a reduction in social investigative activity. Together, this data demonstrates that KDM6B mKO
animals show increased social dominance and exhibit social deficits, as evidenced by decreased social interac-
tion with other animals and behaviors indicative of avoiding direct interaction, as observed in the direct social
interaction paradigm.
Vol.:(0123456789)
www.nature.com/scientificreports/
Fig. 4. Impaired social behaviors of KDM6B mKO animals. (A) Quantification of the number of victories
in the tube dominance test. Each point represents the mean of victories per day 1–4. (B) Quantification of
the time spent in the 3-chamber social interaction test with the novel animal or novel object in Control and
KDM6B mKO animals. (C-E) Direct social interaction test to quantify (C) nose-nose (N–N), (D) nose-head
(N–H), and (E) nose-anogenital (N-A) interactions between Control or KDM6B mKO animals. Bars represents
mean ± SEM. Students t-test was used to determine significance compared to control condition. *p < 0.05,
**p < 0.01, n = 9 animals for Control and KDM6B mKO animals. ns = non-significant.
NMDA receptor mediated synaptic function and plasticity are diminished in KDM6B mKO mice
To investigate the physiological consequences of KDM6B ablation in brain function, we used acute brain slices
from KDM6B mKO animals to perform an electrophysiological characterization of excitatory synaptic activity at
the Schaffer-collateral to CA1 synapse in the hippocampus (Fig. 6A). We first characterized spontaneous AMPA
receptor (AMPAR)-mediated excitatory synaptic activity and found a significant decrease in the frequency but
not in the amplitude of spontaneous excitatory postsynaptic currents (sEPSCs) in KDM6B-deficient synapses
compared to control (Fig. 6B). Likewise, a significant decrease in the frequency of miniature excitatory post-
synaptic currents (mEPSCs) was observed in KDM6B-deficient synapses (Fig. 6C), suggesting that ablation of
KDM6B impact spontaneous excitatory synaptic activity. To further determine whether KDM6B mKO impacts
Vol:.(1234567890)
www.nature.com/scientificreports/
Fig. 5. KDM6B mKO animals display cognitive deficits. (A) Quantification of the total distance travelled in
the Barnes maze apparatus. (B) Primary latency of Control and KDM6B mKO animals in the Barnes maze
apparatus. (C) Quantification of the time spent in the zone of interest where the escape hole was formerly
located. (D) Percentage of time spent freezing by Control and KDM6B mKO animals in the contextual fear
conditioning test. Bars represents mean ± SEM. Students t-test was used to determine significance compared to
control condition. *p < 0.05, **p < 0.01, ***p < 0.001, n = 9 animals for Control and KDM6B mKO animals.
evoked neurotransmitter release probability, we perform paired-pulse ratio measurements at different interstimu-
lus intervals. No differences between control and KDM6B mKO animals were observed (Fig. 6D), suggesting
normal release probability in KDM6B-deficient synapses compared to control synapses. Moreover, no differences
between control and KDM6B mKO animals were observed in AMPAR-mediated fEPSP input–output function
(Fig. 6E), indicating that KDM6B ablation does not affect evoked glutamate release probability and AMPAR-
mediated synaptic transmission in the hippocampus.
Next, we analyzed NMDAR/AMPAR ratios by recording AMPAR-mediated EPSCs at -60 mV and isolated
NMDAR-mediated EPSCs at + 40 mV in the continuous presence of 10 μM NBQX (Fig. 7A). A significant
decrease in the NMDAR/AMPAR ratio was observed in KDM6B mKO deficient synapse compared to control
(Fig. 7A), suggesting a decrease in the total number of NMDARs. To confirm this possibility, we measure isolated
NMDAR-EPSCs input–output curve and found a significant decrease in KDM6B mKO compared to control
animals (Fig. 7B). Moreover, we found that NMDAR-EPSC display significantly slower decay kinetics in KDM6B
mKO mice (Fig. 7C), which could reflect a change in synaptic NMDAR subunit composition32–34. To test this
possibility, we first analyzed the expression of the NMDA receptor subunits NR2A and NR2B in hippocampal
tissue using digital PCR. We found a significant reduction in the number of copies of NR2A cDNA (Fig. 7D) and
an increase in the number of copies of NR2B cDNA (Fig. 7E) in hippocampal tissue of KDM6B mKO animals
compared to control. Second, we performed electrophysiological recording of isolated NMDARs-EPSCs and
used Ro25-6981 (500 nM) to selectively block NR2B-containing NMDARs. We found that NMDAR-EPSCs in
KDM6B mKO mice were more sensitive to Ro25-6981 than controls mice (Fig. 7F). Altogether these results
strongly suggest that KDM6B ablation alters NMDAR-mediated synaptic transmission by decreasing the total
number and the subunit composition of NMDAR present at the Schaffer-collateral to CA1 synapse.
Due to the widespread infection in the animal brain, we also analyzed the effect of KDM6B mKO on synap-
tic function from layer V pyramidal neurons in the medial prefrontal cortex (Supplementary Fig. 1). As in the
hippocampus, we found a significant decrease in the frequency but not in the amplitude of sEPSC in KDM6B-
deficient synapses compared to control (Supplementary Fig. 1). Moreover, NMDAR-mediated EPSC recorded
from KDM6B mKO animals are more sensitive to Ro25-6981 than control cells (Supplementary Fig. 1B), con-
sistent with the idea that KDM6B mKO impact synaptic function and NMDARs subunit composition in both
the cortex and the hippocampus.
Vol.:(0123456789)
www.nature.com/scientificreports/
Changes in NMDARs function has been associated with alteration in the induction of NMDAR-dependent
long-term potentiation (NMDAR-LTP;34). Thereby, we evaluated if NMDAR-LTP is altered by the ablation of
KDM6B and found a strong reduction in the magnitude of LTP in KDM6B mKO mice compared to control
(Fig. 7G). These results indicate that KDM6B plays an important role in NMDAR-dependent synaptic plasticity
in the hippocampus likely by regulating NMDAR expression and activity.
Discussion
Although numerous ASD-related genetic variations are reported, we aimed to deepen our understanding of
the role of KDM6B in regulating chromatin structure and gene transcription in the pathophysiology of ASD
by investigating its effects on behavior and synaptic function. KDM6B is a lysine demethylase responsible for
removing methyl groups from histone H3 lysine 2713, thereby counteracting the repressive effects of the P
RC214
hence facilitating gene expression. In agreement with previous reports in cKO K DM6B23 and heterozygous
Vol:.(1234567890)
www.nature.com/scientificreports/
KDM6B KO animals21, our findings reveal that ablation of brain KDM6B play a critical role in controlling dif-
ferent ASD phenotype including hyperactivity, repetitive behaviors, social interaction, and cognitive deficits.
Synaptic dysfunction is suggested as a core mechanism underlying ASD pathophysiology35. Accordingly, our
results demonstrated that ablation of KDM6B strongly impact NMDAR-mediated synaptic function and plasticity
in the hippocampus, an observation that could explain the cognitive impairments observed in KDM6B mKO
animal. These findings highlight a critical role of KDM6B in the pathophysiology of ASD phenotypes.
Here we utilized CRISPR/Cas9-mediated gene editing to generate KDM6B mKO animals, allowing us to
investigate the behavioral and synaptic consequences of KDM6B deficiency, similarly to what we have previ-
ously done for KMT2C, a histone methyltransferase associated to A SD10. Genetic editing of Kdm6b leads to an
enrichment of H3K27me3, reflecting the deficiency of KDM6B in cells. This dysregulation of histone methyla-
tion suggests a potential mechanism by which KDM6B deficiency may disrupt normal gene expression patterns.
Vol.:(0123456789)
www.nature.com/scientificreports/
Specifically, the increased H3K27me3 levels observed after gene editing likely result in the aberrant silencing
of genes that are normally upregulated by KDM6B-mediated demethylation, as it has been shown in cerebellar
granule neurons where KDM6B deficiency show deficient expression of genes needed for synaptic maturation,
including the predominant NMDA receptor subunit Grin2c36.
The behavioral characterization of the mKO animals reveals the absence of anxiety, as evidenced by results
from the open field, light and dark, and zero maze tests. Surprisingly, in tests such as the rotarod and those previ-
ously mentioned, KDM6B mKO animals exhibited increased locomotion, traveling a longer distance compared
to control animals. Given the absence of anxiety-related behaviors, this heightened activity can be attributed to
hyperactivity in the animals, a trait reminiscent of observations in heterozygous KDM6B a nimals21. In contrast
to findings in Kdm6b heterozygous models, our model system reveals the manifestation of repetitive behaviors
observed in the marble burying and grooming tests. These differences might be a consequence of the differ-
ent approach used to induce KDM6B KO and the extent of KO in different brain areas and cell types. Notably,
KDM6B mKO animals also exhibit significant social impairments, a hallmark trait associated with ASD pheno-
types that has also been observed in human patients carrying KDM6B mutations25.
Although KDM6B mutants in humans have highly variable phenotypes, all of them present cognitive deficits
as a common feature26. In agreement, KDM6B mKO animals display cognitive deficits, as evidenced by impair-
ments in spatial learning and memory formation in the Barnes maze and fear conditioning paradigms. These
findings are in line with existing genetic studies in both humans and mice, which have implicated KDM6B in
intellectual disability and cognitive i mpairment21,24,25,37. It is worth highlighting that, contrary to previous obser-
vations, our study did not identify differences between male and female mice in terms of behavioral outcomes,
thus all our data shows the average obtained from both sexes. This discrepancy could potentially be attributed
to differences in methodology, including the approach used to induce gene editing in both alleles, as opposed to
haploinsufficiency observed in KDM6B heterozygous models.
To gain insight into the mechanisms by which KDM6B deficiency produced autistic-like behaviors, we con-
ducted electrophysiological recording from acute hippocampal slices as this region is mainly implicated in cogni-
tive function. We found that KDM6B mKO has a significant reduction on the frequency of excitatory postsynaptic
currents, however the amplitude was not changed, similarly to what has been observed in other ASD models
including TSC238,CNTNAP2, and A HI139. Furthermore, we looked deeper into the impact on AMPAR-mediated
synaptic transmission, revealing no significant differences compared to control animals. However, a significant
reduction in the AMPAR/NMDAR ratio, indicating a decrease in the total number of NMDAR at the synapse was
found in KDM6B mKO. This characteristic aligns with observations from other animal models of ASD, where a
reduction in NMDAR expression has been documented including neuroligin-1 (NL1) and Shank2 mutants40,41.
To determine the extent to which NMDARs affect synaptic transmission in KDM6B mKO animals, we induced
NMDAR-dependent LTP and found that its induction is severely impaired. This phenomenon has been observed
in other ASD animal models such as T SC238, NL140, and Shank241 mutants among others42.
In addition, our experiments also show that the decay time of NMDA currents is significantly slower in
KDM6B mKO animals in both the hippocampus and medial prefrontal cortex, suggesting a change in the subunit
composition of the NMDARs from the faster NR2A subunit to the slower NR2B kinetics32,43. This was supported
by digital PCR analyses showing that NR2A subunit expression is reduced while NR2B subunit expression is
increased. Future experiments will try to unravel the mechanisms behind this change in NMDA currents.
It has been demonstrated that NMDARs composed of the NR2A subunit are preferentially anchored by PSD95
to the postsynaptic site, whereas NR2B-composed NMDARs are anchored by S AP10244–47. As the expression
of PSD95 is regulated by H 3K27me348,49, it is possible to suggest a link between KDM6B deficiency and altered
PSD95 expression. Since PSD95 serves as the primary anchor for NR2A at the postsynaptic density, the absence
of KDM6B may disrupt the expression of PSD95, consequently impacting the localization of NR2A/PSD95
complexes. Therefore, the disruption of KDM6B function may lead to an imbalance in NMDAR subunit com-
position, thereby influencing synaptic transmission and plasticity. Alternatively, it has been shown that NMDAR
subunits expression during post-natal development is regulated by H 3K27me350, thus KDM6B deficiency may
directly affect the expression of NMDAR subunits impacting synaptic transmission and plasticity. These aspects
warrant further investigations.
Our use of CRISPR/Cas9 to induce a mosaic knockout of KDM6B leads to a significant reduction in KDM6B
expression, likely occurring across a wide range of brain cells as the approach we used is not cell-type specific. As
we are unable to differentiate between cell types or confirm complete knockout in all targeted cells, we acknowl-
edge that our experimental design does not allow us to definitively determine whether the observed effects are
cell-autonomous (neurons) or non-cell-autonomous (e.g. mediated by KDM6B KO in glial cells). Moreover,
it is possible that these effects may arise from a combination of cell-autonomous and non-cell-autonomous
mechanisms. For instance, the disruption of KDM6B in one cell type could indirectly affect neighboring cells
and contribute to the overall phenotype. This limitation is inherent in our approach and should be considered
when interpreting our findings. To address this limitation in future studies, more refined techniques such as
single-cell RNA sequencing or cell-type-specific knockouts would be required to elucidate the precise contribu-
tions of cell-autonomous versus non-cell-autonomous effects.
In conclusion, our approach and mouse model successfully recapitulated the phenotypes observed in humans,
shedding light on the mechanisms through which KDM6B deficiency contributes to ASD phenotypes. Conse-
quently, targeting NMDARs as a therapeutic strategy to address KDM6B brain deficiencies could pave the way
for novel treatments for neurodevelopmental disorders resulting from KDM6B mutations.
Vol:.(1234567890)
www.nature.com/scientificreports/
Methods
Primary neuronal cultures
Postnatal day 1 Cas9 KI mice (C57BL/6J; JAX 026179) were euthanized by decapitation and the whole brain was
extracted in ice cold Ca2+/Mg2+ -free Hank’s balanced salt solution (HBSS). Meninges were removed, the tissue
was minced and incubated with Papain (20 U) for 15 min at 37 °C. Cells were rinsed twice with HBSS, resus-
pended by mechanical agitation through fire-polished glass Pasteur pipettes of decreasing diameters, and plated
over poly-L-lysine-coated culture plates or cover slips. Cultures were maintained at 37 °C in 5% CO2 in growth
media [Neurobasal-A (Life technologies 1088802) supplemented with B27 (Life technologies 17504044), 2 mM
L-glutamine (Life technologies 25030-081), 100 U/ml penicillin/streptomycin (Life technologies 15070–063)].
Half of the media was replaced every 3 days. Neuronal cultures were transduced at 3 days in vitro (DIV) using
concentrated AAV particles.
Plasmids
For the expression of CRISPR/Cas9, plasmids were generated in AAV backbones. For sgRNAs 20nt target
sequences were selected contiguous to a 5′-NGG photospacer-adjacent motif (PAM). sgRNAs for Kdm6b were
designed against exon 6. sgRNA used for in vivo experiments (5′ GGGAAGT TGGAATCCCTACA 3′) were
cloned into a custom AAV plasmid under the control of the U6 promoter, and coding for tdTomato under the
control of the human synapsin1 promoter, as i n10. For viral packaging we used a plasmid coding for the PHP.eB
capsid and pAdDeltaF6 plasmid to express adenovirus E4, E2A and VA genes. pUCmini-iCAP-PHP.eB was a gift
from Viviana Gradinaru (Addgene plasmid # 103005; http://n2t.net/addgene:103005; RRID: Addgene_103005),
pAdDeltaF6 was a gift from James M. Wilson (Addgene plasmid # 112867; http://n2t.net/addgene:112867;
RRID:Addgene_112867).
AAV Production
AAVs were prepared as in10,27. Briefly, AAV particles coding for sgRNA against Kdm6b under the control of
a U6 promoter, together with the red fluorescent protein tdTomato controlled by the hSyn1 promoter were
packed using the PHP.eB capsid to obtain high titer viral p articles10,27,49,53. HEK 293T were transfected with PEI
and PHP.eB capsid plasmids, the vector with Kdm6b sgRNA-tdTomato, and the helper plasmid DF6. After 24
h of transfection, the media was replaced for DMEM 1% FBS. 72 h later, medium was collected from the plates
and replaced with fresh DMEM 1% FBS. The collected medium was stored at 4 °C. To collect the viruses, 120 h
after transfection, the cells were detached from the plate and transferred to 250 mL conical tubes, as well as the
collected media. They were centrifuged for 10 min at 2000g, the supernatant was removed and saved for later
use. The pellet was resuspended in SAN digestion buffer (5 mL of 40 mM Tris, 500 mM NaCl and 2 mM MgCl2
pH 8.0) containing 100U/mL of Salt Active Nuclease (SAN) from Arcticzymes and incubated at 37 °C for 1 h.
To the supernatant that was saved, a 5 × stock solution of 40% PEG 8000 (Sigma Aldrich, USA) in 2.5M NaCl
was added, incubated on ice for 2 h and centrifuged at 4000g for 30 min in 250 mL bottles. The supernatant was
collected and was placed in an Optiprep gradient and ultracentrifuged at 41.000g for 4 h. The phase containing
the AAV was recovered and frozen at – 80 °C for later use.
Vol.:(0123456789)
www.nature.com/scientificreports/
Behavioral overview
All behavioral tests on mice were carried out 8 weeks after AAV injection as in10,27,28. Before each test, mice
cages were transported to the behavior room and habituated for 30 min in the dark. After completing a test,
equipment and devices used were cleaned with 70% ethanol. Tests were recorded and analyzed with ANY-Maze
software (Stoelting, USA).
Rotarod: Mice were placed on an elevated accelerating rod for three trials. Each trial lasted for a maximum of
3 min, during which the Rotarod underwent a linear acceleration of 4 rpm per min. Mean time and speed from
each animal were registered before falling off.
Open Field: Mice were tested in an open field (45 × 45 cm) virtually divided into central and peripheral regions
with ANY-Maze software. Apparatus was illuminated from above with 300 lx in center and 250 lx in periphery.
Animals were allowed to roam freely for 10 min. The total distance traveled and time in center and periphery
were analyzed.
Light and Dark: The apparatus used for this test is a 40 cm box split in half with 390 lx on light side and 0–2
lx on the dark side. Mice were placed in the dark chamber and were allowed to freely explore both chambers for
10 min. Distance traveled, time spent and number of entrances to the light side were analyzed.
Elevated zero-maze: The apparatus consisted of a 46 cm diameter circular runway and raised 54 cm off the
ground. The runway was divided equally into four alternating quadrants of open arcs and closed arcs, with 15
cm walls. Mice started in the center of an open arm and were recorded by video tracking for 10 min. Measures
of cumulative open and closed arc times, total open arm entries, distance in each arm and total distance traveled
were analyzed.
Marble burying test: Mice were tested in a 45 × 45 cm box filled with 5 cm deep wood chips and 49 marbles
distributed in a 7 × 7 pattern. Animals were placed in the test cage and allowed to explore and bury the marbles
during a 30 min session that was videotaped. At the end of the session the subject was removed and the number
of marbles buried (2/3 marble covered by wood chip) were counted.
Contextual fear conditioning: Equipment consisted of a sound attenuating box, fan, light (visible/I.R.), a
speaker, a USB camera, a single on-board controller, and a mouse cage. All trials were recorded, and all mice
underwent a habituation, conditioning and testing phase. During the habituation (day 1): mice were placed in
the fear conditioning cage to explore freely for 5 min and then returned to their cage. During the conditioning
phase (day 2): subject mouse was placed in the fear conditioning cage, let explore freely for 2 min and then sub-
jected to an electric shock of 0.75 mA for 2 s. Next, animal was allowed to explore freely for 3 min and returned
to its cage. On the test phase (day 3): Twenty-four hours after the conditioning phase, the animals were tested
for contextual memory. Each mouse was placed in the fear conditioning box, allowed to freely explore for 5 min,
and returned to its cage. The number and time of freezing episodes was registered.
Barnes Maze: A non-reflective gray circular platform (91 cm diameter) with 20 holes (5 cm diameter) evenly
distributed along the perimeter, with one hole containing a metal escape tunnel was used. Three exogenous
visual cues (length/width ~ 30 cm) were used around the platform: black circle, blue triangle and a yellow square.
Vol:.(1234567890)
www.nature.com/scientificreports/
The light was adjusted to 1000 lx in the center of the platform. All animals underwent a phase of habituation,
spatial acquisition and testing31. For habituation (day 1): each mouse was placed in the center of the platform,
directed towards the escape hole, and allowed to remain there for 1 min. Then it was taken and allowed to freely
explore the maze for 5 min and was again allowed to spend 1 min inside the escape hole. If the mouse did not
enter within 5 min, it was gently guided near the escape hole selected randomly on the table. During training
phase (day 2–4): each animal was introduced into the start box, left in the center of the platform for 10 s and the
start box was removed, and simultaneously a 16,000 Hz sound was played. The test ended at 3 min or when the
mouse has found the escape hole. This procedure was repeated 2 times per day. During those days the following
was recorded: Primary latency: Time to review the escape hole for the first time; Time in the zone of interest;
Total distance traveled. In the test phase (day 5): the position of the escape tunnel was changed, and the animal
was brought in the start box to the center of the platform, left for 10 s and sound reproduction was started. The
test ended at 90 s or when the mouse found the escape tunnel. The number of primary and total errors, primary
and total latency, and total distance before finding the gap were recorded. The number of visits to each hole was
also measured to show preference.
Three-Chamber Sociability and Social Novelty Test: This was performed in a transparent acrylic three-cham-
bered apparatus with the following dimensions: 61.5 × 43.5 × 22 cm. Each outer chamber was 20 × 43.5 cm. We
used small cages of 8 cm diameter and 18 cm height to put the social (unknown WT mice of the same sex and
similar age) and nonsocial stimulus (plastic block of 8 × 4 × 4 cm). A 20 lx illumination was used in this test. On
the habituation phase (day 1): stimulus holders were placed in the center of outer chambers. The subject mouse
was placed in the central chamber and allowed to explore freely for 10 min. Apparatus and stimulus holders
were cleaned between mice with 70% ethanol. During pre-test (day 2): two clean paper balls were prepared and
introduced inside each stimulus holder. The mouse was placed in the central chamber and allowed to explore
freely for 10 min. Apparatus and stimulus holders were cleaned between mice with 70% ethanol. For the social
preference test (day 3): a control mouse was placed in a stimulus holder to be used as a social stimulus and
changed for another one every 2 test runs to avoid burnout or social fatigue54. A plastic block was placed in the
stimulus holder as a nonsocial stimulus. Once social and nonsocial objects were put in the outer chambers, mouse
was placed in the central chamber and allowed to explore freely for 10 min. Behavior was video recorded. Time
amount and distance traveled in the social and nonsocial chamber was registered, as well as the interaction time
with each stimulus. Discrimination index was calculated by (time with novel animal – time with novel object) /
(time with novel animal + time with novel object).
Social Interactions: In this test, an animal from the control condition or KDM6B mKO with a control animal
of the same sex and similar age, were placed in a 30 × 30 × 30 cm box for 10 min. Social interactions (nose-nose
sniffing, nose-face, nose-anogenital area, and grooming) between them were quantified.
Tube dominance: Tube test apparatus consisted of a smooth transparent acrylic tube of 30 cm length and
internal diameter of 2.5 cm. Mice were habituated for 3 days. On day 1, each animal interacted and explored the
tube freely for 30 min. On day 2 and 3, tube inlet was closed, and gel food was placed at the end. Animals were
allowed to explore freely for 30 min. On the training phase (day 4 and 5) mice were taken by the tail and allowed
to freely explore for approximately 1 min on the table where the tube was located. Then they were taken from
the tail and put on one end of the tube and when the animal entered the tail, it was released. If the animal did not
move for several seconds, it was gently prodded with a wooden stick. This step was repeated 5 times per side, so
that the mouse passed through the tube a total of 10 times. The same procedure was repeated on day 4 and 5. On
the test phase (day 6–9): two mice, one control and one KDM6B mKO, were taken and brought to the ends of
the tube by the tail. When they entered completely and reached the middle of the tube, their tails were released
to begin the confrontation. The test was repeated for 4 days. The mouse that pushes and removes its opponent
from the tube was considered the winner and the one that is removed from the tube was considered the loser. All
confrontations were video recorded to analyze the times each animal won and lost. The test stopped when the
loser had all 4 paws out of the tube. The total number of wins and the number of wins per day were compared
between control and KDM6B mKO conditions.
Slice electrophysiology
Acute coronal hippocampal slices (400 μm thick) were prepared from control and KDM6B mKO at postnatal day
(P) 30 to P45 as previously described27,30,49,55,56. Animal handling and use was conducted following a protocol
approved by the Animal Care and Use Committee of the Universidad de Valparaiso (CBC 92-2023) in accordance
with the bioethics regulation of the Chilean Research Council (ANID). Briefly, the brain was isolated and cut
using a DKT vibratome in a solution containing the following (in mM): 215 sucrose, 2.5 KCl, 26 N aHCO3, 1.6
NaH2PO4, 1 CaCl2, 4 MgCl2, 4 MgSO4, and 20 glucose. After 30 min recovery, slices were incubated in an artificial
CSF (ACSF) recording solution containing the following (in mM): 124 NaCl, 2.5 KCl, 26 NaHCO3, 1 NaH2PO4,
2.5 CaCl2, 1.3 MgSO4, and 10 glucose equilibrated with 95% O2/5% CO2, pH 7.4. Slices were incubated in this
solution for 30 min before recordings. For medial prefrontal cortex (mPFC) slices (300 μm thick), brain was
cut in an ice-cold high-choline solution containing (in mM): 110 Choline-Cl, 2.5 KCl, 1.25 N aH2PO4, 7 M gCl2,
25 NaHCO3, 15 glucose, 0.5 C aCl2, 11.6 ascorbate, 3.1 pyruvate (290–305 mmol/Kg) as previously d escribed57.
Vol.:(0123456789)
www.nature.com/scientificreports/
mPFC slices were kept at room temperature for at least 30 min before recording in ACSF containing (in mM):
124 NaCl, 2.69 KCl, 1.25 KH2PO4, 1.3 MgSO4, 26 NaHCO3, 10 glucose, 2.5 CaCl2, pH 7.4 (300–305 mmol/Kg).
All experiments, except where indicated, were performed at 28 ± 1 °C in a submersion-type recording chamber
perfused at 1–2 ml/min rate with ACSF supplemented with the GABAA receptor antagonist picrotoxin (PTX;
100 μM). Extracellular field potentials (fEPSPs) were recorded with a patch pipette filled with 1 mM NaCl and
placed in the CA1 stratum radiatum. Whole-cell voltage-clamp recordings (Multiclamp 700B, Molecular Devices,
USA) were acquired from CA1 pyramidal neurons or layer V pyramidal neurons voltage-clamped at -60 mV
or + 40 mV using patch pipette electrodes (3–4 M) containing the following intracellular solution (in mM): 131
Cs-gluconate, 8 NaCl, 1 C aCl2, 10 EGTA, 10 glucose, 10 HEPES, pH 7.2, 292 mmol/kg osmolality. Reagents were
obtained from Sigma, Tocris and Ascent Scientific, prepared in stock solutions and added to the ACSF as needed.
fEPSPs and excitatory postsynaptic currents (EPSCs) were evoked by stimulating Schaffer collateral inputs in
the hippocampus and layer 2/3 in the mPFC with a monopolar electrode filled with ACSF and positioned ~ 100 to
150 mm away from the recording pipette. Miniature EPSCs (mEPSCs) were recorded at 32 ± 1 °C in the continu-
ous present of tetrodotoxin (TTX, 500 nM) to block action potential dependent release, whereas spontaneous
EPSC (sEPSCs) were recorded in the absence of TTX. Short-term synaptic plasticity was induced by two pulses
at different interstimulus interval (10, 30, 70 100 and 300 ms) and were used to calculated paired-pulse ratio
(PPR) that was defined as the ratio of the slope of the second fEPSP to the slope of the first fEPSP, respectively.
Long-term potentiation (LTP) was induced by 4 trains of 100 pulses at 100 Hz repeated two times, separated
by 10 s. The magnitude of LTP was compared with baseline 30–35 min after applying the stimulation protocol.
To assess cell stability, series and input resistances were monitored with test pulses (− 4 mV, 50 ms) throughout
all experiments. Cells with > 20% change in series resistance were excluded from analysis. All recordings were
elicited at 15–20-s intervals, filtered at 2.4 kHz, and acquired at 10 kHz, using custom made software written in
Igor Pro 6.36 (WaveMetrics). Statistical comparisons were made using two samples Student’s t-test at p < 0.05
significance level, using Origin 8.5 Pro software (OriginLab). Unless otherwise indicated, all electrophysiological
values are provided as mean ± S.E.M and illustrated traces are average of 31–40 responses.
Statistical analysis
Values are presented as mean ± standard error of mean (SEM) for 3 or more independent experiments. Statistical
analyzes with Student’s t-test or Two-samples student t-test was performed. Values of p < 0.05 were considered
statistically significant. All statistical analyzes were performed using Graphpad Prism (GraphPad Software Inc.)
or Origin 9.3 Pro (Origin Lab).
Data availability
All data supporting our conclusions are incorporated in the original manuscript. Other data and material are
available from the corresponding authors upon request.
References
1. Lord, C. et al. Autism spectrum disorder. Nat. Rev. Dis. Prim. 6, 5 (2020).
2. Parenti, I., Rabaneda, L. G., Schoen, H. & Novarino, G. Neurodevelopmental disorders: From genetics to functional pathways.
Trends Neurosci. 43, 608–621 (2020).
3. Banerjee-Basu, S. & Packer, A. SFARI Gene: An evolving database for the autism research community. Dis. Model Mech. 3, 133–135
(2010).
4. Iossifov, I. et al. De novo gene disruptions in children on the autistic spectrum. Neuron 74, 285–299 (2012).
5. Rubeis, S. D. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209–215 (2014).
6. Stessman, H. A. F. et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-
disability biases. Nat. Genet. 49, 515–526 (2017).
7. Grove, J. et al. Identification of common genetic risk variants for autism spectrum disorder. Nat. Genet. 51, 431–444 (2019).
8. Ruzzo, E. K. et al. Inherited and de novo genetic risk for autism impacts shared networks. Cell 178, 850-866.e26 (2019).
9. Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neuro-
biology of autism. Cell 180, 568-584.e23 (2020).
10. Brauer, B., Merino-Veliz, N., Ahumada-Marchant, C., Arriagada, G. & Bustos, F. J. KMT2C knockout generates ASD-like behaviors
in mice. Front. Cell Dev. Biol. 11, 1227723 (2023).
11. Platt, R. J. et al. Chd8 mutation leads to autistic-like behaviors and impaired striatal circuits. Cell reports 19, 335–350 (2017).
12. Tang, G.-B. et al. The histone H3K27 demethylase UTX regulates synaptic plasticity and cognitive behaviors in mice. Front. Mol.
Neurosci. 10, 267 (2017).
13. Agger, K. et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449,
731–734 (2007).
14. Cao, R. et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298, 1039–1043 (2002).
15. Nottke, A., Colaiácovo, M. P. & Shi, Y. Developmental roles of the histone lysine demethylases. Development 136, 879–889 (2009).
16. Burgold, T. et al. The histone H3 lysine 27-specific demethylase jmjd3 is required for neural commitment. PLoS ONE 3, e3034
(2008).
17. Wijayatunge, R. et al. The histone lysine demethylase Kdm6b is required for activity-dependent preconditioning of hippocampal
neuronal survival. Mol. Cell. Neurosci. 61, 187–200 (2014).
18. Park, D. H. et al. Activation of neuronal gene expression by the JMJD3 demethylase is required for postnatal and adult brain
neurogenesis. Cell Rep. 8, 1290–1299 (2014).
19. Shi, Y. Histone lysine demethylases: Emerging roles in development, physiology and disease. Nat. Rev. Genet. 8, 829–833 (2007).
20. Burgold, T. et al. The H3K27 demethylase JMJD3 is required for maintenance of the embryonic respiratory neuronal network,
neonatal breathing, and survival. Cell Rep. 2, 1244–1258 (2012).
Vol:.(1234567890)
www.nature.com/scientificreports/
21. Gao, Y., Aljazi, M. B. & He, J. Kdm6b haploinsufficiency causes ASD/ADHD-like behavioral deficits in mice. Front. Behav. Neurosci.
16, 905783 (2022).
22. Ramesh, V., Liu, F., Minto, M. S., Chan, U. & West, A. E. Bidirectional regulation of postmitotic H3K27me3 distributions underlie
cerebellar granule neuron maturation dynamics. eLife 12, e86273 (2023).
23. Wang, Y. et al. KDM6B cooperates with Tau and regulates synaptic plasticity and cognition via inducing VGLUT1/2. Mol. Psychiatry
27, 5213–5226 (2022).
24. Pineda, I. I. & González, C. L. G. The KDM6B mutation: Phenotype and clinical characteristics—Report of a case. Rev. Psiquiatry
Salud Ment. 15, 88–93 (2022).
25. Stolerman, E. S. et al. Genetic variants in the KDM6B gene are associated with neurodevelopmental delays and dysmorphic features.
Am. J. Méd. Genet. Part A 179, 1276–1286 (2019).
26. Rots, D. et al. The clinical and molecular spectrum of the KDM6B-related neurodevelopmental disorder. Am. J. Hum. Genet. 110,
963–978 (2023).
27. Bustos, F. J. et al. Removal of a partial genomic duplication restores synaptic transmission and behavior in the MyosinVA mutant
mouse Flailer. BMC Biol. 21, 232 (2023).
28. Ahumada-Marchant, C. et al. Deletion of VPS50 protein in mouse brain impairs synaptic function and behavior. BMC Biol. 22,
142 (2024).
29. Silverman, J. L., Yang, M., Lord, C. & Crawley, J. N. Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci.
11, 490–502 (2010).
30. Pandian, S. et al. Myosin va brain-specific mutation alters mouse behavior and disrupts hippocampal synapses. eNeuro 7,
ENEURO.0284-20.2020 (2020).
31. Pitts, M. Barnes maze procedure for spatial learning and memory in mice. BIO-Protoc. 8, e2744 (2018).
32. Sepulveda, F. J. et al. Differential roles of NMDA receptor subtypes NR2A and NR2B in dendritic branch development and require-
ment of RasGRF1. J. Neurophysiol. 103, 1758–1770 (2010).
33. Tindi, J. O. et al. ANKS1B gene product AIDA-1 controls hippocampal synaptic transmission by regulating GluN2B subunit
localization. J. Neurosci. 35, 8986–8996 (2015).
34. Paoletti, P., Bellone, C. & Zhou, Q. NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease.
Nat. Rev. Neurosci. 14, 383–400 (2013).
35. de la Torre-Ubieta, L., Won, H., Stein, J. L. & Geschwind, D. H. Advancing the understanding of autism disease mechanisms
through genetics. Nat. Med. 22, 345–361 (2016).
36. Wijayatunge, R. et al. The histone demethylase Kdm6b regulates a mature gene expression program in differentiating cerebellar
granule neurons. Mol. Cell. Neurosci. 87, 4–17 (2018).
37. Feliciano, P. et al. Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes. NPJ Genom
Med. 4, 19 (2019).
38. Costa, V. et al. mTORC1 inhibition corrects neurodevelopmental and synaptic alterations in a human stem cell model of tuberous
sclerosis. Cell Rep. 15, 86–95 (2016).
39. Sacai, H. et al. Autism spectrum disorder-like behavior caused by reduced excitatory synaptic transmission in pyramidal neurons
of mouse prefrontal cortex. Nat. Commun. 11, 5140 (2020).
40. Budreck, E. C. et al. Neuroligin-1 controls synaptic abundance of NMDA-type glutamate receptors through extracellular coupling.
Proc. Natl. Acad. Sci. 110, 725–730 (2013).
41. Won, H. et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486,
261–265 (2012).
42. Guang, S. et al. Synaptopathology involved in autism spectrum disorder. Front. Cell. Neurosci. 12, 470 (2018).
43. van Zundert, B., Yoshii, A. & Constantine-Paton, M. Receptor compartmentalization and trafficking at glutamate synapses: A
developmental proposal. Trends Neurosci. 27, 428–437 (2004).
44. Bustos, F. J. et al. PSD95 suppresses dendritic arbor development in mature hippocampal neurons by occluding the clustering of
NR2B-NMDA receptors. PLoS ONE 9, e94037 (2014).
45. Elias, G. M., Elias, L. A. B., Apostolides, P. F., Kriegstein, A. R. & Nicoll, R. A. Differential trafficking of AMPA and NMDA recep-
tors by SAP102 and PSD-95 underlies synapse development. Proc. Natl. Acad. Sci. USA 105, 20953–20958 (2008).
46. Sans, N. et al. A developmental change in NMDA receptor-associated proteins at hippocampal synapses. J. Neurosci. 20, 1260–1271
(2000).
47. Elias, G. M. et al. Synapse-specific and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding
proteins. Neuron 52, 307–320 (2006).
48. Henriquez, B. et al. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons. Mol.
Cell. Neurosci. 57, 130–143 (2013).
49. Bustos, F. J. et al. Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer’s disease mice. Brain 140,
3252–3268 (2017).
50. Rodenas-Ruano, A., Chávez, A. E., Cossio, M. J., Castillo, P. E. & Zukin, R. S. REST-dependent epigenetic remodeling promotes
the developmental switch in synaptic NMDA receptors. Nat. Neurosci. 15, 1382–1390 (2012).
51. Kim, J.-Y., Grunke, S. D., Levites, Y., Golde, T. E. & Jankowsky, J. L. Intracerebroventricular viral injection of the neonatal mouse
brain for persistent and widespread neuronal transduction. J. Vis. Exp. 91, 51863 (2014).
52. Passini, M. A. & Wolfe, J. H. Widespread Gene delivery and structure-specific patterns of expression in the brain after intraven-
tricular injections of neonatal mice with an adeno-associated virus vector. J. Virol. 75, 12382–12392 (2001).
53. Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat.
Neurosci. 20, 1172–1179 (2017).
54. Rein, B., Ma, K. & Yan, Z. A standardized social preference protocol for measuring social deficits in mouse models of autism. Nat.
Protoc. 15, 3464–3477 (2020).
55. Delgado-Acevedo, C. et al. Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased
EAAT3 expression. Neuropsychopharmacology 44, 1163–1173 (2019).
56. Plaza-Briceño, W. et al. N-Methyl-d-aspartate receptor modulation by nicotinamide adenine dinucleotide phosphate oxidase type 2
drives synaptic plasticity and spatial memory impairments in rats exposed pre- and postnatally to ethanol. Antioxid. Redox Signal.
32, 602–617 (2020).
57. Cortés, B. I. et al. Loss of protein tyrosine phosphatase receptor delta PTPRD increases the number of cortical neurons, impairs
synaptic function and induces autistic-like behaviors in adult mice. Biol. Res. 57(1), 40 (2024).
Acknowledgements
This work was supported by: ANID Fondecyt Iniciacion 11180540 (FJB), ANID PAI 77180077 (FJB), Explo-
ración-ANID 13220203 (FJB), ANID-MILENIO (NCN2023_32, FJB, LVN), UNAB DI-02-22/REG (FJB), Fond-
equip EQM230028 (FJB), UNAB DI-06-24/REG (FJB), ANID-FONDECYT 1220480 (GA), ANID-FONDECYT
1201848 (A.E.C), ANID-FONDECYT 1230454 (LVN), DI-03-21/APP UNAB (BB), Fondequip EQM160154
Vol.:(0123456789)
www.nature.com/scientificreports/
(A.E.C) and by ANID Millennium Science Initiative Program (P09-022F to A.E.C). R.C.M was supported by
ANID-FONDECYT postdoctorado grant #3190793. CA-G and NM-V were supported by PhD fellowship from
ANID #21201603 (to CA-G) and #21211967 (to NM-V).
Author contributions
B.B, N.M-V, and C.A-M performed all behavioral experiments and analyzed the results. C.A-G, and R.C.M
performed all slices electrophysiological experiments and analyzed the results. F.J.B, G.N, L.V–N, G.A, and
A.E.C designed experiments, guided the research, provided resources, and interpreted all the results. F.J.B, and
A.E.C., wrote the paper.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-024-70728-5.
Correspondence and requests for materials should be addressed to A.E.C. or F.J.B.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives
4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide
a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have
permission under this licence to share adapted material derived from this article or parts of it. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and
your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/
licenses/by-nc-nd/4.0/.
Vol:.(1234567890)